为把握长期市场机遇，公司持续强化核心竞争力：研发投入显著增加，重点加大对AI赋能科研、单细 胞与空间多组学、蛋白质与代谢组学解决方案及临床转化等前沿方向的投入，以增强产品领先性。 格隆汇2月26日丨诺禾致源(688315.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入22.10亿 元，同比增长4.66%；实现归属于母公司所有者的净利润1.66亿元，同比减少15.59%；实现归属于母公 司所有者的扣除非经常性损益的净利润1.28亿元，同比减少24.75%。 报告期末，公司总资产39.82亿元，相比2024年末增长9.50%；归属于母公司的所有者权益26.48亿元， 相比2024年末增长6.33%。报告期内，面对宏观环境与部分客户短期经费的波动，公司积极应对，营业 收入仍实现稳健增长。 ...

北京诺禾致源科技股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以北京诺禾致源科技股份有限公司（以下简称"公司"）2025年年 度报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 | 项目 | 本报告期 | 上年同期 | 增减变动幅 | | --- | --- | --- | --- | | | | | 度（％） | | 营业总收入 | 220,963.79 | 211,131.92 | 4.66 | | 营业利润 | 19,351.92 | 23,397.02 | -17.29 | | 利润总额 | 19,292.79 | 22,472.75 | -14.15 | | 归属于母公司所有者的 净利润 | 16,611.27 | 19,678.85 | -15.59 | | 归属于母公司所有者的 扣除非经常性损益的净 | 12,849.23 | 17,075.98 | -24.7 ...

资料显示，北京诺禾致源科技股份有限公司位于北京市朝阳区酒仙桥北路甲10号院301号楼101栋，成立 日期2011年3月15日，上市日期2021年4月13日，公司主营业务涉及为科研机构、高校、医疗机构、药业 等企事业单位提供基因检测和生物信息分析等研究服务。主营业务收入构成为：测序平台服务 50.03%，生命科学基础科研服务34.05%，医学研究与技术服务13.37%，其他2.21%，其他(补 充)0.33%。 截至9月30日，诺禾致源股东户数9680.00，较上期减少1.24%；人均流通股42995股，较上期增加 1.26%。2025年1月-9月，诺禾致源实现营业收入15.81亿元，同比增长4.05%；归母净利润1.13亿元，同 比减少16.05%。 分红方面，诺禾致源A股上市后累计派现8247.08万元。近三年，累计派现5845.88万元。 2月24日，诺禾致源跌0.52%，成交额5618.33万元。两融数据显示，当日诺禾致源获融资买入额1125.10 万元，融资偿还542.17万元，融资净买入582.93万元。截至2月24日，诺禾致源融资融券余额合计1.44亿 元。 融资方面，诺禾致源当日融资买入1125 ...

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

北京诺禾致源科技股份有限公司 内部审计制度 二〇二六年一月 （三）保障公司资产的安全； 第一章 总则 第一条 为了加强和规范北京诺禾致源科技股份有限公司（以下简称"公 司"）内部审计工作，明确内部审计职责，建立健全有效的内部监督体系，提高 公司抗风险能力，根据《中华人民共和国审计法》《上海证券交易所科创板股票 上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等相关法律法规，结合本公司实际情况，特制定本度。 第二条 本制度所称内部审计，是指公司内部审计机构或人员依据国家有关 法律法规和本制度的规定，对本公司各内部机构、控股子公司以及具有重大影响 的参股公司的内部控制和风险管理的有效性、财务信息的真实性、完整性以及经 营活动的效率和效果等开展的一种评价活动。 第三条 本制度所称内部控制，是指公司董事会、审计委员会、高级管理 人员及其他有关人员为实现下列目标而提供合理保证的过程： （一）遵守国家法律、法规、规章及其他相关规定； （四）确保公司信息披露的真实、准确、完整和公平。 北京诺禾致源科技股份有限公司 内部审计制度 （二）提高公司经营的效率和效果； 第四条 公司董事会应当对内部控制 ...

Core Viewpoint - The medical services sector experienced a rise of 1.19% on January 23, with notable gains from companies like Nuohua Zhiyuan, which led the sector's performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1]. - The medical services sector saw significant individual stock movements, with Nuohua Zhiyuan (688315) closing at 17.00, up 13.26%, and Hai Te Biological (300683) closing at 33.31, up 7.66% [1]. Group 2: Trading Volume and Value - Nuohua Zhiyuan had a trading volume of 219,500 shares and a transaction value of 365 million yuan [1]. - Hai Te Biological recorded a trading volume of 190,900 shares with a transaction value of 632 million yuan [1]. Group 3: Capital Flow - The medical services sector saw a net inflow of 999.1 million yuan from institutional investors, while retail investors experienced a net outflow of 1.069 billion yuan [2]. - The capital flow data indicates that major stocks like Diyan Diagnosis (300244) had a net inflow of 288 million yuan from institutional investors [3].

Group 1 - The Shanghai Composite Index closed at 4136.16 points, above the five-day moving average, with a gain of 0.33% [1] - The total trading volume of A-shares reached 31,181.08 billion yuan [1] - A total of 1,091 A-shares have prices that surpassed the five-day moving average, with notable stocks including Dongfang Risheng, Jinko Solar, and Xinke Mobile, showing divergence rates of 16.59%, 15.85%, and 15.78% respectively [1] Group 2 - The top stocks with significant divergence rates from the five-day moving average include: - Dongfang Risheng (300118) with a price increase of 20.00% and a divergence rate of 16.59% [1] - Jinko Solar (688223) also increased by 20.00% with a divergence rate of 15.85% [1] - Xinke Mobile (688387) rose by 18.41% with a divergence rate of 15.78% [1] - Other notable stocks with divergence rates include: - Jiejia Weichuang (300724) at 20.00% increase and 15.34% divergence [1] - Ruichuang Micro (688002) with a 20.00% increase and 14.83% divergence [1]

Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index closing at 4133.58 points, above the five-day moving average, reflecting a gain of 0.27% [1] Group 1: Market Performance - The total trading volume of A-shares reached 19,136.04 billion yuan [1] - A total of 961 A-shares have prices that surpassed the five-day moving average [1] Group 2: Individual Stock Performance - Notable stocks with significant deviation rates from the five-day moving average include: - Dongfang Risheng (300118) with a deviation rate of 16.59% and a price increase of 20.00% [2] - Jiejia Weichuang (300724) with a deviation rate of 15.34% and a price increase of 20.00% [2] - Ruichuang Weina (688002) with a deviation rate of 14.83% and a price increase of 20.00% [2] - Other stocks with notable performance include: - Jingke Energy (688223) with a deviation rate of 14.43% and a price increase of 18.09% [2] - Guosheng Tang (300436) with a deviation rate of 14.19% and a price increase of 20.00% [2]

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]

Market Overview - The Shanghai Composite Index closed at 4120.10 points, above the annual line, with a change of 0.16% [1] - The total trading volume of A-shares reached 1,645.83 billion yuan [1] Stocks Above Annual Line - A total of 61 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Huawi Design (华维设计) with a deviation rate of 24.42% - Hualing Co. (华岭股份) at 5.51% - Huilong Piston (汇隆活塞) at 4.81% [1] Detailed Stock Performance - The following table summarizes the performance of selected stocks that have crossed the annual line: - Huawi Design (华维设计): Today's change of 29.96%, turnover rate of 26.39%, annual line at 14.64 yuan, latest price at 18.22 yuan [1] - Hualing Co. (华岭股份): Today's change of 12.70%, turnover rate of 9.21%, annual line at 24.90 yuan, latest price at 26.27 yuan [1] - Huilong Piston (汇隆活塞): Today's change of 18.06%, turnover rate of 13.30%, annual line at 9.86 yuan, latest price at 10.33 yuan [1] - Other notable stocks include: - Wuhan Fangu (武汉凡谷) with a deviation rate of 4.17% - Meirui New Materials (美瑞新材) with a deviation rate of 3.81% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the annual line include: - Gongdong Medical (拱东医疗) and Chongqing Gas (重庆燃气) [1] - The performance of these stocks indicates a cautious upward trend in the market [1]